CNBX Pharmaceuticals Inc.

CNBX

US13764M2098

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:42:22 2024-04-26 pm EDT			5-day change	1st Jan Change
0.0108 ^USD	-16.92%		-5.26%	-23.94%

Apr. 16	CNBX Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	CI
Jan. 12	CNBX Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023	CI

Shaul Yemal Resigns Position as Director and Board Member Cnbx Pharmaceuticals Inc

December 29, 2022 at 02:52 pm EST

CNBX Pharmaceuticals Inc. On December 25th, 2022, Shaul Yemal resigned his position as Director and Board Member. Shaul's resignation was not the result of any dispute with the Company.

Latest news about CNBX Pharmaceuticals Inc.

CNBX Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	Apr. 16	CI
CNBX Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023	Jan. 12	CI
CNBX Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended August 31, 2023	Nov. 30	CI
CNBX Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023	23-07-14	CI
CNBX Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2023	23-04-14	CI
CNBX Pharmaceuticals Inc. Announces Board Resignations	23-02-08	CI
CNBX Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended November 30, 2022	23-01-13	CI
Shaul Yemal Resigns Position as Director and Board Member Cnbx Pharmaceuticals Inc	22-12-29	CI
CNBX Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended August 31, 2022	22-11-30	CI
CNBX Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt	22-11-29	CI
CNBX Pharmaceuticals Inc. acquired unknown stake in TaGeza Biopharmaceuticals Ltd.	22-11-07	CI
CNBX Pharmaceuticals Inc. Announces That the Company Has Filed A New Patent Application Titled " Compositions Comprising Cannabinoids and Methods of Use Thereof in the Treatment of Cancer" Under the Patent Cooperation Treaty	22-10-18	CI
CNBX Pharmaceuticals Inc. Announces Executive Changes	22-07-25	CI
CNBX Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2022	22-07-14	CI
CNBX Pharmaceuticals Inc. Receives Grant of Patent Notice by the Patent Registry, Intellectual Property Department, the Government of the Hong Kong Special Administrative Region	22-05-05	CI
CNBX Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2022	22-04-12	CI
Cannabics Pharmaceuticals Inc. has Changed its Name to CNBX Pharmaceuticals Inc	22-03-28	CI
Cannabics Pharmaceuticals Inc. Enters into Forbearance Agreement with an Institutional Investor	22-02-17	CI
CNBX Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended November 30, 2021	22-01-13	CI
CNBX Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended August 31, 2021	21-11-29	CI
CNBX Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt	21-11-28	CI
Cannabics Pharmaceuticals Inc. Appoints Shaul Yemal as an Independent Director and as A Member of the Audit Committee	21-11-19	CI
Cannabics Pharmaceuticals Inc. Appoints Yonina Tova to Board of Advisors	21-10-25	CI
Cannabics Pharmaceuticals Inc. Files 2 Provisional Patents on Compositions and Methods for Treating Cancer	21-10-18	CI
Neuropsychiatry Expert Dr. Ilya Reznik (MD) Joins Cannabics as Head of Psychedelic Inspired Medicine	21-09-13	CI

Chart CNBX Pharmaceuticals Inc.

Duration

Period

More charts

CNBX Pharmaceuticals Inc. is a clinical-stage company specializing in the discovery, development and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. The Company's lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome (CACS). Its anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) is RCC-33, a therapy being developed primarily in two settings: one to reduce tumor cell activity in CRC patients as a standalone in neoadjuvant treatment or window of opportunity at the time after colonoscopy, prior to cancer staging, and another for patients with refractory to therapy and adjuvant to surgery also at the time after colonoscopy. The Company indents to initiate Phase I/II clinical trials for both candidates: Cannabics SR and RCC-33.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CNBX PHARMACEUTICALS INC.	-23.94%	336K
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B